You searched for: deferoksaminom (Slovenska - Engelska)

za bolnike, ki so dobro urejeni z deferoksaminom
for patients well managed on deferoxamine

13 ki je trajala dve leti, so deferipron primerjali z deferoksaminom.
in one study of two-year duration deferiprone was compared to deferoxamine.

v eni od študij, ki je trajala dve leti, so deferipron primerjali z deferoksaminom.
serum ferritin was chosen as the primary efficacy criterion in the studies.

6 bolnikih, ki so se zdravili z deferipronom, povečala bolj kot pri bolnikih, zdravljenih z deferoksaminom.
the mean serum ferritin levels were not significantly different in the two treatment groups, but mean hepatic iron concentration in deferiprone treated patients seems to increase more than in deferoxamine treated patients.

ferriprox se uporablja za zdravljenje prenasičenosti z železom pri bolnikih z veliko talasemijo za katere je zdravljenje z deferoksaminom kontraindicirano ali neustrezno.
ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.

pri kronični preobremenitvi z železom zaradi transfuzij krvi so v eni glavni študiji zdravilo exjade primerjali z deferoksaminom pri 591 bolnikih z beta talasemijo major.
in chronic iron overload due to blood transfusions, exjade was investigated in one main study comparing exjade with deferoxamine in 591 patients with beta thalassaemia major.

v objavljeni študiji je zdravilo ferriprox v kombinaciji z deferoksaminom povzročilo tudi večje zmanjšanje železa v srcu v primerjavi z bolniki, ki so jemali samo deferoksamin.
in a published study, ferriprox together with deferoxamine also led to greater decreases in iron in the heart compared with patients taking deferoxamine alone.

objavljene študije o uporabi zdravila ferriprox z deferoksaminom kažejo na večje znižanje ravni feritina v krvi pri uporabi kombinacije obeh zdravil v primerjavi z uporabo vsakega zdravila samostojno.
published studies on use of ferriprox together with deferoxamine reported greater reductions in blood ferritin levels when both medicines were used in combination compared with using either medicine on its own.

v primeru srčnega popuščanja zaradi železa je treba terapiji z deferoksaminom dodati zdravilo ferriprox 75–100 mg/kg/dan.
in the case of iron-induced heart failure, ferriprox at 75-100 mg/kg/day should be added to deferoxamine therapy.

osnovna analiza podatkov ključne primerjalne študije s 586 bolniki z beta talasemijo in s preobremenitvijo z železom zaradi transfuzij ni dokazala neinferiornosti deferasiroksa v obliki disperzibilnih tablet v primerjavi z deferoksaminom v analizi celotne populacije bolnikov.
the principal analysis of the pivotal comparative study in 586 patients suffering from beta-thalassaemia and transfusional iron overload did not demonstrate non-inferiority of deferasirox dispersible tablets to deferoxamine in the analysis of the total patient population.

v študiji zdravljenja z izmenjevanjem zdravil je urnik zdravljenja, po katerem so kombinirali pet dni zdravljenja z zdravilom ferriprox in dva dni z deferoksaminom, znižal ravni feritina v krvi v enaki meri kot zdravljenje samo z deferoksaminom.
in the alternating treatment study, the treatment schedule combining ferriprox for five days with deferoxamine for two days reduced blood ferritin levels to the same extent as deferoxamine taken on its own.

prišlo je do izboljšanja v srčnem t2* za več kot 3 milisekunde pri pacientih, ki so jih zdravili z zdravilom ferriprox v primerjavi s spremembo približno 1 milisekunde pri pacientih, ki so jih zdravili z deferoksaminom.
there was an improvement in cardiac t2* of more than 3 milliseconds in patients treated with ferriprox compared with a change of about 1 millisecond in patients treated with deferoxamine.

zdravilo exjade je indicirano tudi za zdravljenje kronične preobremenitve z železom, ko je zdravljenje z deferoksaminom kontraindicirano ali neprimerno pri bolnikih, ki potrebujejo terapijo s kelacijo železa in so stari 10 let ali več ter imajo katerega od sindromov talasemije, neodvisnih od transfuzij.
exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.

zdravilo exjade uporabljamo tudi za zdravljenje kronične preobremenitve z železom v primerih, ko je zdravljenje z deferoksaminom kontraindicirano ali neprimerno pri bolnikih z beta talasemijo major s preobremenitvijo z železom zaradi manj pogostih transfuzij krvi, pri bolnikih z drugimi vrstami slabokrvnosti in pri otrocih, starih od 2 do 5 let.
exjade is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.

2 pri bolnikih, ki so ob zdravljenju z deferoksaminom že dobro urejeni, je lahko primeren začetni odmerek zdravila exjade številčno enak polovici odmerka deferoksamina (npr. bolnik, ki prejema 40 mg/ kg/ dan deferoksamina 5 dni na teden (ali temu ekvivalenten odmerek), lahko preide na začetni dnevni odmerek 20 mg/ kg/ dan zdravila exjade).
for patients already well managed on treatment with deferoxamine, a starting dose of exjade that is numerically half that of the deferoxamine dose could be considered (e. g. a patient receiving 40 mg/ kg/ day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 20 mg/ kg/ day of exjade).